Froment, Laurène

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2020 | 2019 | 2017 | 2016 | 2015 | 2014

2020

Wang, Limei; Dorn, Patrick; Simillion, Cedric; Froment, Laurène; Berezowska, Sabina Anna; Tschanz, Stefan A.; Haenni, Beat; Blank, Fabian; Wotzkow, Carlos; Peng, Ren-Wang; Marti, Thomas; Bode, Peter Karl; Moehrlen, Ueli; Schmid, Ralph; Hall, Sean (2020). EpCAM+CD73+ mark epithelial progenitor cells in postnatal human lung and is associated with pathogenesis of pulmonary disease including lung adenocarcinoma. American journal of physiology - lung cellular and molecular physiology, 319(5), L794-L809. American Physiological Society 10.1152/ajplung.00279.2019

Wang, Limei; Dorn, Patrick; Zeinali, Soheila; Froment, Laurène; Berezowska, Sabina; Kocher, Gregor; Alves, Marco P; Brügger, Melanie; Esteves, Blandina I.O.; Blank, Fabian; Wotzkow, Carlos; Steiner, Selina; Amacker, Mario; Peng, Ren-Wang; Marti, Thomas; Guenat, Olivier Thierry; Bode, Peter Karl; Moehrlen, Ueli; Schmid, Ralph and Hall, Sean (2020). CD90+CD146+ identifies a pulmonary mesenchymal cell subtype with both immune modulatory and perivascular-like function in postnatal human lung. American journal of physiology - lung cellular and molecular physiology, 318(4), L813-L830. American Physiological Society 10.1152/ajplung.00146.2019

2019

Shun-Qing, Liang; Bührer, Elias; Berezowska, Sabina Anna; Marti, Thomas; Xu, Duo; Froment, Laurène; Yang, Haitang; Hall, Sean; Vassella, Erik; Zhang, Yang; Kocher, Gregor; Amrein, Michael Alex; Riether, Carsten; Ochsenbein, Adrian; Schmid, Ralph; Peng, Ren-Wang (2019). mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. Oncogene, 38(5), pp. 622-636. Nature Publishing Group 10.1038/s41388-018-0479-6

2017

Marti, Thomas; Tièche, Colin; Peng, Ren-Wang; Hall, Sean; Froment, Laurène; Dorn, Patrick; Berezowska, Sabina Anna; Schmid, Ralph (7 May 2017). Characterizing the DNA damage response in putative stem cells of resected normal lung and matched NSCLC patient samples. Annals of oncology, 28(suppl_2), ii4. Oxford University Press 10.1093/annonc/mdx090.013

Bichsel, Colette; Wang, Limei; Froment, Laurène; Berezowska, Sabina Anna; Müller, Stefan Jürg; Dorn, Patrick; Marti, Thomas M.; Peng, Ren-Wang; Geiser, Thomas; Schmid, Ralph A.; Guenat, Olivier Thierry; Hall, Sean (2017). Increased PD-L1 expression and IL-6 secretion characterize human lung tumor-derived perivascular-like cells that promote vascular leakage in a perfusable microvasculature model. Scientific Reports, 7(1), p. 10636. Nature Publishing Group 10.1038/s41598-017-09928-1

2016

Hall, Sean; Wang, Limei; Marti, Thomas; Peng, Ren-Wang; Froment, Laurène; Berezowska, Sabina Anna; Kocher, Gregor; Dorn, Patrick; Schmid, Ralph (2016). 10PD Assessment of PD-L1 and CD47 expression together with tumor-associated TILs in resectable early stage NSCLC. Annals of oncology, 27(suppl_8), viii3. Oxford University Press 10.1093/annonc/mdw525.09

Hall, Sean; Wang, Limei; Marti, Thomas; Peng, Ren-Wang; Froment, Laurène; Berezowska, Sabina Anna; Kocher, Gregor; Dorn, Patrick; Schmid, Ralph (2016). 98O: Characterization of tumor infiltrating lymphocytes in resectable early stage non-small cell lung cancer. Journal of thoracic oncology, 11(4Suppl), S99-S99. Elsevier 10.1016/S1556-0864(16)30211-8

Marti, Thomas; Dorn, Patrick; Tièche, Colin; Peng, Ren-Wang; Froment, Laurène; Schmid, Ralph (2016). 23P Prolonged pemetrexed pretreatment increases efficiency of ionizing radiation combination therapy and correlates with the persistence of treatment-induced DNA damage in lung cancer cells. Journal of thoracic oncology, 11(4Suppl), S65-S65. Elsevier 10.1016/S1556-0864(16)30137-X

Marti, Thomas; Tièche, Colin; Peng, Ren-Wang; Dorn, Patrick; Froment, Laurène; Schmid, Ralph (2016). 22P Increased schedule-dependent efficiency of pemetrexed-cisplatin combination therapy eliminates resistant lung cancer stem-like cells associated with EMT. Journal of thoracic oncology, 11(4Suppl), S64-S65. Elsevier 10.1016/S1556-0864(16)30136-8

Shun-Qing, Liang; Marti, Thomas; Dorn, Patrick; Froment, Laurène; Hall, Sean; Berezowska, Sabina Anna; Kocher, Gregor; Schmid, Ralph; Peng, Ren-Wang (2016). 18P Epithelial-to-mesenchymal transition (EMT) is required for resistance to anti-folate chemotherapy in lung cancer. Journal of thoracic oncology, 11(4Suppl), S63-S63. Elsevier 10.1016/S1556-0864(16)30132-0

Tièche, Colin; Peng, Ren-Wang; Dorn, Patrick; Froment, Laurène; Schmid, Ralph; Marti, Thomas (2016). Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT. BMC cancer, 16(125), p. 125. BioMed Central 10.1186/s12885-016-2117-4

Cortes, Lourdes; Froment, Laurène; Kocher, Gregor; Schmid, Ralph (2016). Human lung-derived mesenchymal stem cell-conditioned medium exerts in vitro antitumor effects in malignant pleural mesothelioma cell lines. Stem cell research & therapy, 7(1), p. 25. BioMed Central 10.1186/s13287-016-0282-7

Dorn, Patrick; Tièche, Colin; Peng, Ren-Wang; Froment, Laurène; Schmid, Ralph; Marti, Thomas (2016). Schedule-dependent increased efficiency of pemetrexed-ionizing radiation combination therapy elicits a differential DNA damage response in lung cancer cells. Cancer cell international, 16(66), p. 66. BioMed Central 10.1186/s12935-016-0346-x

2015

Shun-Qing, Liang; Marti, Thomas; Dorn, Patrick; Froment, Laurène; Hall, Sean; Berezowska, Sabina Anna; Kocher, Gregor; Schmid, Ralph; Peng, Renwang (2015). Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer. Cell death & disease, 6(e1824), e1824. Nature Publishing Group 10.1038/cddis.2015.195

2014

Cortes-Dericks, Lourdes; Froment, Laurène; Boesch, Ruben; Schmid, Ralph; Karoubi, Golnaz (2014). Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity. BMC cancer, 14, p. 304. BioMed Central 10.1186/1471-2407-14-304

Provide Feedback